Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.

Abstract: A compound of formula (I), (IA) or formula (II) or a composition comprising the compound of formula (I), (IA) or formula (II) in association with a veterinarily acceptable carrier are described. A method of controlling helminths using same is described.

Abstract: The disclosure provides compounds that inhibit protein tyrosine phosphatase, such as protein tyrosine phosphatase 4 A3 (PTP4A3). The disclosure also provides pharmaceutical compositions, uses, and methods of using the compounds, such as in the treatment of cancers.

Abstract: Disclosed is a method for synthesizing an O-antigen saccharide chain of Helicobacter pylori serotype O:6 using seven glycosylation building blocks. Inexpensive and easily available D-glucosamine, D-galactose, D-mannose and L-fucose are used as starting materials, and seven glycosylation building blocks are obtained through a series of chemical reactions. The saccharide building blocks are then selectively linked together to produce O-antigen oligosaccharide chains of Helicobacter pylori serotype O:6 with different saccharide configuration through a series of glycosylation reactions. Also disclosed is a method to assemble an amino linker at the reducing end of the O-antigen saccharide chain of Helicobacter pylori serotype O:6, and the synthesized oligosaccharide chain with an amino linker can be coupled to a carrier molecule or immobilized on a matrix.